The relevance of this study is conditioned by the significant prevalence of chronic kidney disease in cats and the prominent role of calcium-phosphorus metabolism disorders in its progression and the development of complications, which requires further scientific attention to improve approaches to animal treatment. The purpose of this review was to summarise modern scientific data on the influence of calcium and phosphorus on the course of chronic kidney disease in cats and to formulate recommendations for nutritional support. A systematic approach was employed to search and analyse scientific literature for 2020-2025. The review analysed the results of modern studies on the diagnostics of chronic nephropathy in small carnivores, clinical recommendations, and expert opinions in the field of veterinary medicine. The study found that the excess phosphorus content in the diet of animals directly correlates with the acceleration of disease progression, the development of secondary hyperparathyroidism, soft tissue calcification, and deterioration of the functional state of the kidneys. At the same time, excessive decrease in phosphorus concentration can cause hypercalcemia, loss of appetite, vomiting, and other metabolic disorders. The optimal diet for animals with chronic kidney disease is a calcium to phosphorus ratio within the range of 1.1:11.5:1. The study considered role of modern biomarkers, such as symmetrical dimethylarginine and fibroblast growth factor-23, in the early diagnosis and monitoring of chronic kidney disease. The study also analysed the efficacy of dietary therapy, particularly the use of phosphate binders, active forms of vitamin D, probiotics, antioxidants, and agents for the correction of acid-base homeostasis. A review of the literature confirmed that efficacious nutritional management is a key factor in the control of chronic kidney disease. The findings obtained emphasised the significance of developing optimal dietary strategies that account for both the phosphorus level and the calcium to phosphorus ratio in the blood serum. This will inhibit the progression of the disease and improve the quality of life of cats with chronic kidney disease
mineral homeostasis; veterinary dietetics; electrolyte metabolism; metabolic disorders; hypercalcemia; hyperphosphatemia; phosphate binders
[1] Beita, K.G., Lourenço, B.N., Rehagen, M., & Schmiedt, C.W. (2024). Effect of aluminium hydroxide on serum phosphate and fibroblast growth factor 23 concentrations in young adult cats with surgically induced chronic kidney disease. American Journal of Veterinary Research, 85(10). doi: 10.2460/ajvr.24.04.0123.
[2] Biasibetti, E., Martello, E., Bigliati, M., Biasato, I., Cocca, T., Bruni, N., & Capucchio, M.T. (2018). A long-term feed supplementation based on phosphate binders in feline chronic kidney disease. Veterinary Research Communications, 42(2), 161-167. doi: 10.1007/s11259-018-9719-z.
[3] Brown, S.A., Rickertsen, M., & Sheldon, S. (2008). Effects of an intestinal phosphorus binder on serum phosphorus and parathyroid hormone concentration in cats with reduced renal function. International Journal of Applied Research in Veterinary Medicine, 6(3), 155-160.
[4] Chen, H.-Y., Sun, C.-Y., Lee, C.-C., Wu, I.-W., Chen, Y.-C., Lin, Y.-H., Fang, W.-C., & Pan, H.-C. (2021). Ketoanalogue supplements reduce mortality in patients with pre-dialysis advanced diabetic kidney disease: A nationwide population-based study. Clinical Nutrition, 40(6), 4149-4160. doi: 10.1016/j.clnu.2021.01.045.
[5] Chew, D.J. (2022). Optimizing phosphorus control in chronic kidney disease. Clinical Notes, 1-3.
[6] Clark, S. (2024). Stem cell therapy for canine and feline patients with chronic kidney disease. (Honors thesis, Murray State University, Murray, USA).
[7] Coady, M., Fletcher, D.J., & Goggs, R. (2019). Severity of ionized hypercalcemia and hypocalcemia is associated with etiology in dogs and cats. Frontiers in Veterinary Science, 6, article number 276. doi: 10.3389/fvets.2019.00276.
[8] Costa, R.C.C., Pereira, J.A.S., Alexandrowitsch, F.C.F., Filho, M.D.F.F., Lemes, B.C., Cunha, R.D.O., Ferreira, T.L., de Carvalho, N.L., & Guedes, E. (2024). Evaluation of the applicability of SDMA for early diagnosis of CKD in felines and survey of staging and tests used in routine practice. Seven Editora, 412-427. doi: 10.56238/sevened2024.025-033.
[9] Cozzolino, M., Fusaro, M., Ciceri, P., Gasperoni, L., & Cianciolo, G. (2019). The role of vitamin K in vascular calcification. Advances in Chronic Kidney Disease, 26(6), 437-444. doi: 10.1053/j.ackd.2019.10.005.
[10] Danks, L. (2015). The nutritional management of feline chronic kidney disease. Companion Animal, 20(3), 162-167. doi: 10.12968/coan.2015.20.3.162.
[11] Elder, G.J., & Center, J. (2017). The role of calcium and non calcium-based phosphate binders in chronic kidney disease. Nephrology, 22(2), 42-46. doi: 10.1111/nep.13031.
[12] Ephraim, E., & Jewell, D.E. (2020). Effect of added dietary betaine and soluble fiber on metabolites and fecal microbiome in dogs with early renal disease. Metabolites, 10(9), article number 370. doi: 10.3390/metabo10090370.
[13] Felsenfeld, A.J., Levine, B.S., & Rodriguez, M. (2015). Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Seminars in Dialysis, 28(6), 564-577. doi: 10.1111/sdi.12411.
[14] Geddes, R.F., van den Broek, D.H.N., Chang, Y.-M., Biourge, V., Elliott, J., & Jepson, R.E. (2021). The effect of attenuating dietary phosphate restriction on blood ionized calcium concentrations in cats with chronic kidney disease and ionized arcalcemia. Journal of Veterinary Internal Medicine, 35(2), 997-1007. doi: 10.1111/jvim.16050.
[15] Hahn, L., & Callaband, C. (2022). Review of chronic kidney disease and comparison between humans, dogs, and cats. Journal of Student Research, 11(3). doi: 10.47611/jsrhs.v11i3.2999.
[16] Hokamp, J.A., & Nabity, M.B. (2016). Renal biomarkers in domestic species. Veterinary Clinical Pathology, 45(1), 28-56. doi:10.1111/vcp.12333.
[17] Jewell, D.E., Tavener, S.K., Hollar, R.L., & Panickar, K.S. (2022). Metabolomic changes in cats with renal disease and calcium oxalate uroliths. Metabolomics, 18(8), article number 68. doi: 10.1007/s11306-022-01925-4.
[18] Kim, J.W., & Yang, S.J. (2025). Dietary patterns, kidney function, and sarcopenia in chronic kidney disease. Nutrients, 17(3), article number 404. doi: 10.3390/nu17030404.
[19] Korman, R.M., & White, J.D. (2013). Feline CKD: Current therapies – what is achievable? Journal of Feline Medicine and Surgery, 15(1), 29-44. doi: 10.1177/1098612X13495241.
[20] Kramer, H. (2019). Diet and chronic kidney disease. Advances in Nutrition, 10(4), 367-379. doi: 10.1093/advances/nmz011.
[21] Lin, J., Lin, L., Chen, S., Yu, L., Chen, S., & Xia, Z. (2021). Serum fibroblast growth factor 23 (FGF-23): associations with hyperphosphatemia and clinical staging of feline chronic kidney disease. Journal of Veterinary Diagnostic Investigation, 33(2), 288-293. doi: 10.1177/1040638720985563.
[22] Lu, H., et al. (2025). Dietary addition of magnesium hydride nanoparticles: A breakthrough in combating high-fat diet-induced chronic kidney disease. Medical Gas Research, 15(3), 374-382. doi: 10.4103/mgr.MEDGASRES-D-24-00090.
[23] Meineri, G., Saettone, V., Radice, E., Bruni, N., Martello, E., & Bergero, D. (2021). The synergistic effect of prebiotics, probiotics and antioxidants on dogs with chronic kidney disease. Italian Journal of Animal Science, 20(1), 1079-1084. doi: 10.1080/1828051X.2021.1940323.
[24] Nagode, L.A., Chew, D.J., & Podell, M. (1996). Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure: Both are essential to prevent or suppress toxic hyperparathyroidism. Veterinary Clinics of North America: Small Animal Practice, 26(6), 1293-1330. doi: 10.1016/S0195-5616(96)50130-0.
[25] Parker, V.J. (2021). Nutritional management for dogs and cats with chronic kidney disease. Veterinary Clinics of North America: Small Animal Practice, 51(3), 685-710. doi: 10.1016/j.cvsm.2021.01.007.
[26] Pedrinelli, V., Lima, D.M., Duarte, C.N., Teixeira, F.A., Porsani, M., Zarif, C., Amaral, A.R., Vendramini, T., Kogika, M.M., & Brunetto, M.A. (2020). Nutritional and laboratory parameters affect the survival of dogs with chronic kidney disease. PLOS One, 15(6), article number e0234712. doi: 10.1371/journal.pone.0234712.
[27] Peek, J.L., & Wilson, M.H. (2023). Cell and gene therapy for kidney disease. Nature Reviews Nephrology, 19, 451-462. doi: 10.1038/s41581-023-00702-3.
[28] Perondi, F., Lippi, I., Bruni, N., Lonigro, N., & Martello, E. (2025). Effect of a feed supplement containing probiotics on fecal score and clinical parameters in dogs with chronic kidney disease and intestinal disorders: A pilot study. Open Veterinary Journal, 15(1), 307-313. doi: 10.5455/OVJ.2025.v15.i1.29.
[29] Polzin, D.J. (2013). Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. Journal of Veterinary Emergency and Critical Care, 23(2), 205-215. doi: 10.1111/vec.12034.
[30] Pusoonthornthum, R., Vimuktanandana, O., Pusoonthornthum, P., Rungsipipat, A., & Krishnamra, N. (2011). Calcium-phosphorus homeostasis in cats with spontaneous chronic kidney disease and metabolic acidosis. Comparative Clinical Pathology, 21(5), 985-991. doi: 10.1007/s00580-011-1213-8.
[31] Rodríguez-Osorio, L., Pazmiño Zambrano, D., Gracia-Iguacel, C., Rojas-Rivera, J., Ortiz, A., Egido, J., & González Parra, E. (2015). Use of sevelamer in chronic kidney disease: Beyond phosphorus control. Nefrología, 35(2), 207-217. doi: 10.1016/j.nefro.2015.05.022.
[32] Seiler, S., Heine, G.H., & Fliser, D. (2009). Clinical relevance of FGF-23 in chronic kidney disease. Kidney International, 76(114), S34-S42. doi: 10.1038/ki.2009.405.
[33] Shipov, A., Segev, G., Meltzer, H., Milgram, J., Brenner, O., Shahar, R., & Kelmer, E. (2014). The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone. PLOS One, 9(10), article number e110057. doi: 10.1371/journal.pone.0110057.
[34] Stockman, J. (2024). Dietary phosphorus and renal disease in cats: Where are we? Journal of Feline Medicine and Surgery, 26(10). doi: 10.1177/1098612X241283355.
[35] Sugisawa, R., et al. (2016). Impact of feline AIM on the susceptibility of cats to renal disease. Scientific Reports, 6, article number 35251. doi: 10.1038/srep35251.
[36] Tang, P.-K., Geddes, R.F., Chang, Y.-M., Jepson, R.E., Bijsmans, E., & Elliott, J. (2021). A feline-focused review of chronic kidney disease-mineral and bone disorders. Part 2: Pathophysiology of calcium disorders and extraosseous calcification. The Veterinary Journal, 275, article number 105718. doi: 10.1016/j.tvjl.2021.105718.
[37] Tavakolidakhrabadi, N., Ding, W.Y., Saleem, M.A., Welsh, G.I., & May, C. (2024). Gene therapy and kidney diseases. Molecular Therapy. Methods & Clinical Development, 32(4), article number 101333. doi: 10.1016/j.omtm.2024.101333.
[38] Tsai, S.-H., Kan, W.-C., Jhen, R.-N., Chang, Y.-M., Kao, J.-L., Lai, H.-Y., Liou, H.-H., & Shiao, C.-C. (2024). Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy. Clinical Medicine, 24(5), article number 100238. doi: 10.1016/j.clinme.2024.100238.
[39] Vorland, C.J., Biruete, A., Lachcik, P.J., Srinivasan, S., Chen, N.X., Moe, S.M., & Hill Gallant, K.M. (2020). Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease-mineral bone disorder. Journal of Bone and Mineral Research, 35(2), 333-342. doi: 10.1002/jbmr.3894.
[40] Zafalon, R.V.A., Risolia, L.W., Pedrinelli, V., Vendramini, T.H.A., Rodrigues, R.B.A., Amaral, A.R., Kogika, M.M., & Brunetto, M.A. (2020). Vitamin D metabolism in dogs and cats and its relation to diseases not associated with bone metabolism. Journal of Animal Physiology and Animal Nutrition, 104(1), 322-342. doi: 10.1111/jpn.13259.
[41] Zhang, W., Lou, B., Peng, Y., Wu, F., Zhang, D., & Wang, Q. (2024). High dietary calcium to phosphorus ratio is associated with high prevalence of kidney stone. Medicine, 103(50), article number e40778. doi: 10.1097/MD.0000000000040778.